Kyverna Therapeutics (KYTX) Interest Expenses (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Interest Expenses came in at $35.1 million in Q1 2026, up 3547.25% YoY from $963000.0 in Q1 2025, and up 9793.8% on a QoQ basis from $355000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) Interest Expenses (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Interest Expenses data on file, last reported at $35.1 million in Q1 2026.
- Quarterly Interest Expenses rose 3547.25% year-over-year to $35.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.1 million (up 668.56% YoY) and the FY2025 annual result came in at $43.8 million, up 1326.0% from the prior year.
- Interest Expenses rose to $35.1 million in Q1 2026, from $355000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $35.1 million in Q1 2026 to a low of $47000.0 in Q4 2023.
- A 4-year average of $6.4 million and a median of $1.8 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses surged 6193.62% — and 2025, when it plunged 88.0%.
- Tracing KYTX's Interest Expenses over 4 years: stood at $47000.0 in 2023, then surged by 6193.62% to $3.0 million in 2024, then sank by 88.0% to $355000.0 in 2025, then jumped by 9793.8% to $35.1 million in 2026.
- The last three Interest Expenses figures came in at $35.1 million (Q1 2026), $355000.0 (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 32.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.71 Mn |
| Jun 30, 2026 | 32.71 Mn |
| Mar 31, 2026 | 35.12 Mn |
| Mar 31, 2026 | 35.12 Mn |
| Dec 31, 2025 | 355,000.00 |
| Dec 31, 2025 | 355,000.00 |
| Sep 30, 2025 | 16.12 Mn |
| Sep 30, 2025 | 16.12 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 963,000.00 |
| Mar 31, 2025 | 963,000.00 |
| Dec 31, 2024 | 2.96 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | 8.87 Mn |
| Sep 30, 2024 | 8.87 Mn |
| Jun 30, 2024 | 12.63 Mn |
| Jun 30, 2024 | 12.63 Mn |
| Mar 31, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.80 Mn |